S. Nair

发表

Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.

D. Sargent, S. Thibodeau, R. Goldberg, 2012, JAMA.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

F. Cappuzzo, D. Gandara, D. Planchard, 2015, The Lancet. Oncology.

Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

M. Zaaroor, U. Bogdahn, K. Schlingensiepen, 2010, Neuro-oncology.

Current immunotherapeutic strategies in malignant melanoma.

S. Nair, P. Mosca, Nicole M. Agostino, 2007, Surgical oncology clinics of North America.

Sex differences in fluorouracil-induced stomatitis.

J. Sloan, P. Novotny, J. Sloan, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group.

E. Perez, J. Jett, S. Hillman, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.

D. Moore, N. Foster, K. Rowland, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.

D. Sargent, J. Donohue, R. Goldberg, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer.

S. Cha, D. Sargent, J. Sloan, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NSCLC, metastaticCheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC

M. Socinski, D. Carbone, S. Peters, 2016 .

Cediranib (AZD2171) in Patients With Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group Clinical Trial

S. Dakhil, S. Alberts, S. Nair, 2012, American journal of clinical oncology.

Pilot study of human recombinant interferon gamma and accelerated hyperfractionated thoracic radiation therapy in patients with unresectable stage IIIA/B nonsmall cell lung cancer.

E. Shaw, S. Nair, E. Creagan, 1995, International journal of radiation oncology, biology, physics.

Phase II trial of topotecan for the treatment of mesothelioma.

J. Jett, R. Marks, S. Nair, 1998, American journal of clinical oncology.

Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance).

D. Sargent, R. Goldberg, A. Shields, 2017 .

Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).

D. Sargent, J. Galon, A. Shields, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.

V. Khoo, H. Pandha, S. Nair, 2007, The Journal of urology.

Dramatic Response to Concurrent Anti-PD-1 Therapy and Radiation in Resistant Tumors with Sarcomatoid Differentiation.

S. Nair, R. Nair, A. Mcintosh, 2018, The oncologist.

Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study)

J. Wolchok, A. Shoushtari, M. Callahan, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prediction of pan-solid tumor pembrolizumab benefit by integrating tumor mutation and gene expression profiling

Nickolay A. Khazanov, M. Burkard, D. Rhodes, 2022 .

A Randomized Phase II and Pharmacokinetic Study of Dacarbazine in Patients with Recurrent Glioma

B. Scheithauer, J. Buckner, S. Vincent Rajkumar, 2000, Journal of Neuro-Oncology.

Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia.

S. Nair, R. Nair, Shereen M. F. Gheith, 2016, The New England journal of medicine.

FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC).

R. Motzer, T. Choueiri, W. Miller, 2020 .

Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial.

A. Benson, J. Galon, R. Goldberg, 2022, JCO precision oncology.

Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).

D. Sargent, A. Benson, J. Galon, 2018 .

Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).

D. Sargent, A. Benson, J. Galon, 2017 .

A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia

D. Sargent, R. Goldberg, K. Rowland, 2002, International journal of gastrointestinal cancer.

Pemetrexed (Pem)/gemcitabine (Gem) as front-line therapy for advanced NSCLC: A randomized, phase II trial of three schedules.

J. Jett, S. Mandrekar, A. Adjei, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary Small Cell Anaplastic Carcinoma of the Breast Diagnosed by Fine Needle Aspiration Cytology

S. Nair, M. Šebenik, H. Hamati, 1998, Acta Cytologica.

Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity.

Thomas K. Schulz, J. Krook, J. Kugler, 2004, Lung cancer.

Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147.

D. Sargent, S. Thibodeau, R. Goldberg, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147

D. Sargent, S. Thibodeau, R. Goldberg, 2010 .

Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial.

R. Day, J. Kirkwood, R. Bahnson, 1992, Cancer research.

Interferon-induced reversible acute renal failure with nephrotic syndrome.

J. Kirkwood, R. Bahnson, M. Ernstoff, 1992, Urology.

A phase II study of paclitaxel plus carboplatin as first‐line chemotherapy for women with metastatic breast carcinoma

E. Perez, L. Hartmann, J. Ingle, 2000, Cancer.

Taxane-based Induction Chemotherapy Plus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma: Prospective Results from a Non-endemic Cohort.

P. Chaturvedi, S. Nair, P. Pai, 2019, Clinics in oncology.

A Phase II NCCTG Study of Irinotecan and Docetaxel in Previously Treated Patients with Non-Small Cell Lung Cancer

J. Jett, S. Hillman, K. Rowland, 2006, Cancer investigation.

Combined levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma: a phase II study.

J. Krook, J. Kugler, S. Nair, 1998, American journal of clinical oncology.

A North Central Cancer Treatment Group Phase II Trial of Topotecan in Relapsed Gliomas

B. Scheithauer, T. Cascino, J. Buckner, 2000, Investigational New Drugs.

First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer

M. Socinski, D. Carbone, S. Peters, 2017, The New England journal of medicine.

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.

C. Horak, R. Sullivan, J. Sosman, 2016, The Lancet. Oncology.

Phase II North Central Cancer Treatment Group study of 2-cholorodeoxyadenosine in patients with recurrent glioma.

B. Scheithauer, J. O'fallon, R. Dinapoli, 1999, American journal of clinical oncology.

Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)

D. Sargent, R. Goldberg, A. Shields, 2016, The oncologist.

KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)

D. Sargent, S. Thibodeau, R. Goldberg, 2014, Clinical Cancer Research.

Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147.

D. Sargent, S. Thibodeau, R. Goldberg, 2014, Clinical colorectal cancer.

Diagnostic Value of 68Ga PSMA-11 PET/CT Imaging of Brain Tumors—Preliminary Analysis

S. Nair, J. Madhavan, A. Sasikumar, 2017, Clinical nuclear medicine.

Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer.

C. Obasaju, J. Jett, S. Mandrekar, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prospective evaluation of the role of Vascular Endothelial Growth Factor (VEGF) and the immune system in stage III/IV melanoma

S. Nair, S. Markovic, W. Nevala, 2015, SpringerPlus.

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

R. Kurzrock, C. Blanke, S. Nair, 2021, Journal for ImmunoTherapy of Cancer.

Fibroblast Growth Factor Receptor 3 Amplified Metastatic Melanoma Treated With Erdafitinib

A. Shoushtari, M. Callahan, S. Nair, 2020, Cureus.

LBA-17 MULTICENTER PROSPECTIVE PHASE II CLINICAL TRIAL OF GEMCITABINE AND CISPLATIN AS NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH HIGH-GRADE UPPER TRACT UROTHELIAL CARCINOMA

J. Coleman, D. Sjoberg, G. Iyer, 2019, Journal of Urology.

Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.

D. Sargent, S. Thibodeau, R. Goldberg, 2014, Journal of the National Cancer Institute.

Current Clinical Trials in the Treatment of Advanced Melanomas.

S. Nair, Rohit Sharma, S. Sarkisian, 2020, The Surgical clinics of North America.

Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas

N. Schultz, J. Wolchok, N. Rosen, 2021, Clinical Cancer Research.

Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck

J. Kugler, S. Nair, V. Suman, 2002, Cancer.

Clinical characteristics and treatment-related biomarkers associated with response to high-dose interleukin-2 in metastatic melanoma and renal cell carcinoma: retrospective analysis of an academic community hospital’s experience

S. Nair, Nicole M. Agostino, M. J. Weiss, 2015, SpringerPlus.

Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma

A. Hakimi, H. Vargas, J. Coleman, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.

R. Day, J. Kirkwood, R. Bahnson, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CPT-11 for bile-duct and gallbladder carcinoma

R. Goldberg, L. Burgart, S. Alberts, 2002, International journal of gastrointestinal cancer.

Genetic Variant Associated with Survival of Patients with Stage II-III Colon Cancer.

Stephanie A. Bien, A. Joshi, Wei Sun, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

795 A multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Michael R. Wagner, R. Kurzrock, S. Nair, 2020 .

Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer

A. Benson, J. Galon, R. Goldberg, 2020, JNCI cancer spectrum.

Risk stratification after recurrence of human papillomavirus (HPV)‐related and non‐HPV‐related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522

M. Birrer, Q. Le, H. Bahig, 2021, Head & neck.

LTBK-04. PHASE 2 MULTICENTER STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 (TASADENOTUREV) IN COMBINATION WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)

T. Cloughesy, H. Colman, M. Daras, 2020 .

A front‐line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer

S. Mandrekar, S. Hillman, S. Nair, 2010, Cancer.

Pilot studies of the north central cancer treatment group (NCCTG) utilizing accelerated hyperfractionated thoracic radiation therapy (AHTRT) in unresectable stage IIIA/B non-small cell lung cancer (NSCLC)

E. Shaw, J. Jett, S. Nair, 1994 .

Long-Term Survival of Patients With Advanced/Recurrent Carcinoma of Cervix and Vagina After Neoadjuvant Treatment With Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without the Addition of Molgramostim, and Review of the Literature

L. Hartmann, S. Nair, V. Suman, 2002, American journal of clinical oncology.

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).

D. Sargent, R. Diasio, Adam M. Lee, 2016, Pharmacogenetics and genomics.

Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147

D. Sargent, P. Newcomb, R. Goldberg, 2016, International Journal of Cancer.

Phase II Evaluation of 96-Hour Paclitaxel Infusion in Advanced (Recurrent or Metastatic) Squamous Cell Carcinoma of the Head and Neck (E3395): A Trial of the Eastern Cooperative Oncology Group

S. Nair, C. Langer, R. Cohen, 2004, Cancer investigation.

Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800).

J. Manola, G. Wilding, M. Carducci, 2015, Clinical genitourinary cancer.

N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC)

E. Perez, S. Nair, T. Hobday, 2005 .

Quality of life (QOL) for patients treated with FOLFOX with or without cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147.

D. Sargent, J. Sloan, R. Goldberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer

D. Gandara, D. Planchard, S. Ramalingam, 2014 .

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

Takafumi N. Yamaguchi, R. Stupp, W. Mason, 2023, Nature Network Boston.

In vitro Generation and in vivo Effects of Adherent Lymphokine-Activated Killer Cells and IL2 in Patients with Solid Tumors1

J. Kirkwood, T. Whiteside, M. Ernstoff, 1990 .

Investigating four 'myths' surrounding dysphagia in patients with metastatic esophageal cancer. A multi-institutional study from the North Central Cancer Treatment Group.

N. Foster, S. Nair, R. Morton, 2004, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma

Suresh Nair, S. Nair, N. Ellison, 2002, Cancer.

Discordance of receptor status in breast cancer throughout tumor progression and the associated prognostic implications: A case report and review of the literature

S. Nair, Laura Spranklin, 2016 .

A phase II study to evaluate the need for > two doses of nivolumab + ipilimumab combination (combo) immunotherapy.

J. Wolchok, A. Shoushtari, M. Callahan, 2020 .

Durable clinical benefit from combination ipilimumab (IPI) and nivolumab (NIVO) in anti-PD-1 therapy resistant, platinum resistant metastatic urothelial carcinoma (mUC).

E. Ziv, J. Wolchok, G. Iyer, 2019, Journal of Clinical Oncology.

23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)

C. Horak, R. Sullivan, J. Sosman, 2015 .

A Retrospective Review of Stage III Unresectable and Stage IV Extracranial Cancers Treated with Concurrent and Sequential PD-1 Inhibitors and Ablative Radiation Therapy at LVHN

S. Nair, A. Mcintosh, S. Adediran, 2019 .

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

F. Cappuzzo, D. Gandara, D. Planchard, 2015, The Lancet. Oncology.

Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147

D. Sargent, P. Newcomb, R. Goldberg, 2016, International journal of cancer.

Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma

S. Nair, A. Blackham, Angela Miller, 2022, Cureus.